Baohui Han: Clinical Trials

3 trials sponsored by Baohui Han, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 not yet recruiting, 1 unknown. 3 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Completed 1, Not yet recruiting 1, Unknown 1
Phase 11Not yet recruiting 1

Follow Baohui Han: new trials by email

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy
Adebrelimab, Irinotecan Liposome (II), Adebrelimab, Irinotecan Liposome (II), Famitinib - Extensive-stage Small-cell Lung Cancer
Phase 1 / Phase 2Not yet recruitingBaohui Han802024-04-012024-03-27
Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns
Aumolertinib - Lung Cancer
Phase 2UnknownBaohui Han1042022-01-142023-04-21
Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.
erlotinib - Non Small Cell Lung Cancer
Phase 2CompletedBaohui Han252011-03-022017-09-12

Conditions studied

Carcinoma, Non-Small-Cell Lung (1)  ·  Lung Neoplasms (1)  ·  Small Cell Lung Carcinoma (1)

Interventions

Erlotinib Hydrochloride (1)  ·  aumolertinib (1)  ·  famitinib (1)  ·  irinotecan sucrosofate (1)

Countries

China (3)

Results publications

PMID 30158288, PMID 31885349